TrialAmerican journal of hematology2019

Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Talha Munir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.